Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications

Superparamagnetic iron oxide nanoparticles can providemultiple benefits for biomedical applications in aqueous environments such asmagnetic separation or magnetic resonance imaging. To increase the colloidal stability and allow subsequent reactions, the introduction of hydrophilic functional groups onto the particles’ surface is essential. During this process, the original coating is exchanged by preferably covalently bonded ligands such as trialkoxysilanes. The duration of the silane exchange reaction, which commonly takes more than 24 h, is an important drawback for this approach. In this paper, we present a novel method, which introduces ultrasonication as an energy source to dramatically accelerate this process, resulting in high-quality waterdispersible nanoparticles around 10 nmin size. To prove the generic character, different functional groups were introduced on the surface including polyethylene glycol chains, carboxylic acid, amine, and thiol groups. Their colloidal stability in various aqueous buffer solutions as well as human plasma and serum was investigated to allow implementation in biomedical and sensing applications.status: publishe

Site- and allele-specific polycomb dysregulation in T-cell leukaemia

International audienc

Continuity and Change in Gang Membership and Gang Embeddedness

Objectives. Drawing from social network and life-course frameworks, the authors extend Hagan's concept of criminal embeddedness to embeddedness within gangs. This study explores the relationship between embeddedness in a gang, a type of deviant network, and desistance from gang membership. Method. Data were gathered over a five-year period from 226 adjudicated youth reporting gang membership at the baseline interview. An item response theory model is used to construct gang embeddedness. The authors estimate a logistic hierarchical linear model to identify whether baseline levels of gang embeddedness alter the longitudinal contours of gang membership. Results. Gang embeddedness is associated with slowing the rate of desistance from gang membership over the full five-year study period. Gang members with low levels of embeddedness leave the gang quickly, crossing a 50 percent threshold in six months after the baseline interview, whereas high levels of embeddedness delays similar reductions until about two years. Males, Hispanics, and Blacks were associated with greater continuity in gang membership as well as those with low self-control. Conclusions. The concept of gang embeddedness broadens understanding of heterogeneity in deviant network immersion and is applicable to a wide range of criminal and delinquent networks. Gang embeddedness has implications for studying the parameters of gang careers and for a range of criminological outcomes.No Full Tex

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk